Compare BWA & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWA | DVA |
|---|---|---|
| Founded | 1987 | 1994 |
| Country | United States | United States |
| Employees | N/A | 78000 |
| Industry | Auto Parts:O.E.M. | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 9.9B |
| IPO Year | 1995 | 2002 |
| Metric | BWA | DVA |
|---|---|---|
| Price | $57.42 | $154.05 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 4 |
| Target Price | $59.33 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 1.5M | 571.2K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.28 | ★ 9.84 |
| Revenue | ★ $14,316,000,000.00 | $13,643,069,000.00 |
| Revenue This Year | $1.54 | $3.85 |
| Revenue Next Year | $3.54 | $3.07 |
| P/E Ratio | $42.25 | ★ $15.47 |
| Revenue Growth | 1.63 | ★ 6.46 |
| 52 Week Low | $28.92 | $101.00 |
| 52 Week High | $70.08 | $159.42 |
| Indicator | BWA | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 60.70 | 57.16 |
| Support Level | $51.43 | $144.98 |
| Resistance Level | $70.08 | $157.49 |
| Average True Range (ATR) | 1.46 | 3.59 |
| MACD | 0.15 | 0.24 |
| Stochastic Oscillator | 96.44 | 85.67 |
BorgWarner is a tier one supplier of turbo and thermal management technologies, drivetrain systems, powerdrive systems, and battery and charging systems mostly to automotive original equipment manufacturers. Its products aim to move a vehicle with as few electrons as possible, resulting in cleaner, cost-optimized, and more-efficient vehicles. Foundational products, the combustion vehicle business, contributes more than 80% to group revenue while BorgWarner transitions to becoming an electric vehicle-centric parts supplier (e-business). In 2024, 23% of the company's revenue was sourced from Volkswagen and Ford. Revenue is well diversified geographically, with approximately a third each generated in North America, Europe, and Asia.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.